CellGate

About:

anti-proliferative drugs

Top Investors: New Enterprise Associates, HealthCare Ventures, Johnson & Johnson Development Corporation, Sprout Group

Description:

Progen Pharmaceuticals, Inc. develops pharmaceutical products for the treatment of anti-proliferation and cancer therapeutics. The company's products are also used for the treatment of various diseases, including age-related macular degeneration, infectious diseases, inflammatory diseases, and vascular hyperplasia. Progen Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Redwood City, California. Progen Pharmaceuticals, Inc. was formerly known as CellGate, Inc. As a result of the acquisition of Cellgate, Inc. by Progen Pharmaceuticals Limited, Cellgate's name was changed. As of February 7, 2008, Progen Pharmaceuticals, Inc. operates as a subsidiary of Progen Pharmaceuticals Limited (ASX: PGL).

Total Funding Amount:

$72.9M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Redwood City, California, United States

Founded Date:

1998-01-01

Founders:

Edgar G. Engleman

Number of Employees:

1-10

Last Funding Date:

2003-06-17

IPO Status:

Private

Industries: